These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 22506625

  • 1. Effectiveness of adjuvant imatinib in patients with gastrointestinal stromal tumor: results of a population-based, matched-cohort study.
    Hatoum HT, Lin SJ, Sasane M, Trent JC.
    Curr Med Res Opin; 2012 May; 28(5):805-14. PubMed ID: 22506625
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
    McAuliffe JC, Lazar AJ, Yang D, Steinert DM, Qiao W, Thall PF, Raymond AK, Benjamin RS, Trent JC.
    Clin Cancer Res; 2007 Nov 15; 13(22 Pt 1):6727-34. PubMed ID: 18006774
    [Abstract] [Full Text] [Related]

  • 7. A study of the postoperative course in cases of GIST of the stomach. The efficacy of imatinib in cases of recurrence.
    Higashi D, Watanabe Y, Hirano K, Shimomura T, Egawa Y, Tomiyasu T, Ishibashi Y, Futami K, Maekawa T, Ota A, Oshige K, Iwashita A.
    Anticancer Res; 2009 Nov 15; 29(11):4893-6. PubMed ID: 20032453
    [Abstract] [Full Text] [Related]

  • 8. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
    Cao H, Zhang Y, Wang M, Shen DP, Sheng ZY, Ni XZ, Wu ZY, Liu Q, Shen YY, Song YY.
    Chin Med J (Engl); 2010 Jan 20; 123(2):131-6. PubMed ID: 20137358
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients.
    Streit F, Binder L, Hafke A, Brandhorst G, Braulke F, Haase D, Armbrust T, Cameron S, Ramadori G, Oellerich M, Walson P.
    Ther Drug Monit; 2011 Oct 20; 33(5):632-43. PubMed ID: 21912334
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A, den Bakker MA, van Geel AN, Eggermont AM, Sleijfer S, Verweij J, de Wilt JH, Verhoef C.
    Anticancer Drugs; 2008 Jul 20; 19(6):607-12. PubMed ID: 18525320
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).
    Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S, Pennacchioli E, Casali PG, Gronchi A.
    Eur J Surg Oncol; 2009 Jul 20; 35(7):739-45. PubMed ID: 19110398
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
    Majer IM, Gelderblom H, van den Hout WB, Gray E, Verheggen BG.
    J Med Econ; 2013 Sep 20; 16(9):1106-19. PubMed ID: 23808902
    [Abstract] [Full Text] [Related]

  • 17. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era.
    Bonvalot S, Eldweny H, Péchoux CL, Vanel D, Terrier P, Cavalcanti A, Robert C, Lassau N, Cesne AL.
    Ann Surg Oncol; 2006 Dec 20; 13(12):1596-603. PubMed ID: 16957966
    [Abstract] [Full Text] [Related]

  • 18. [Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial].
    Zhan WH, Wang PZ, Shao YF, Wu XT, Gu J, Li R, Wan DS, Ding KF, Shi YQ, Yu JR, Lu HS, Zou XM, Bi JW, Sun YH, Lu YF, Chen DD, Zhang XH.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Sep 20; 9(5):383-7. PubMed ID: 17043955
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.